Incannex Healthcare Inc. · NASDAQ:IXHL
Incannex Healthcare — Merger or Acquisition (May 2022)
27 slides from Incannex Healthcare's merger presentation, May 12, 2022
Slide 1: APIRx Pharmaceuticals Acquisition
APIRx Pharmaceuticals Acquisition May 2022 ASX Ticker: IHL | NASDAQ Ticker: IXHL Exciting projects, strategic patents, cannabinoid expertise and synergies.
Slide 2: Disclosure and Disclaimer
Disclosure and Disclaimer Not an offer of Securities This document has been independently prepared by Incannex Healthcare Limited (Incannex) and is provided for informational purposes only . This document does not constitute or contain an offer, invitation, solicitation or recommendation with respec
Slide 3: The acquisition of APIRx delivers a strong portfolio of patented drug candidates
The acquisition of APIRx delivers a strong portfolio of patented drug candidates, with 22 development programs covering a total addressable market of US$400B per annum. Together, Incannex and APIRx will form the world’s largest portfolio of patented medicinal cannabinoid drug formulations and psyche
Slide 4: Acquisition of APIRx Pharmaceuticals USA, LLC
– Drug candidates are expertly designed to target irritable bowel syndrome, addiction disorders, spasticity and pain in multiple sclerosis, nausea and vomiting in chemotherapy, inflammatory bowel disease, periodontal disease and gingivitis, skin conditions, ophthalmic conditions, dementia, Parkinson
Slide 5: Benefits of the APIRx Acquisition
Benefits of the APIRx Acquisition 01. Substantial IP portfolio covering active pharmaceutical ingredients, formulations and methods of use to secure commercial exclusivity. – Developed technologies and IP at all stages of cannabinoid drug development from extraction to therapeutic uses. 02. Clinical
Slide 6: Benefits of the APIRx Acquisition (continued)
Benefits of the APIRx Acquisition 06. Over - the - counter (OTC) patented CBD chewable tablet relevant to a range of ailments being planned for the CheWell high - bioavailability oral mucosa dosage form. – Therapeutic Goods Administration (TGA) limits on daily CBD dosage for OTC cannabinoid products
Slide 7: Clinical Project Addressable Market Opportunity
Clincial Project Addressable Market Opportunity (in US$) Stage of Development Regulatory Stage of Development Next Steps Relevant Patents MedChew Π- 1401 Pain and Spasticity in Multiple Sclerosis $62B (Global) in '21 (a) Pre - clinical Pre - IND completed in NL and Switzerland Phase 1 Granted MedCh
Slide 8: Clinical Project Addressable Market Opportunity (continued)
Clincial Project Addressable Market Opportunity (in US$) Stage of Development Regulatory Stage of Development Next Steps Relevant Patents CheWell Addiction: Cannabis Dependence $64B (U.S.) in '21 (c) Pre - clinical Pre - IND ready for submission Phase 1 Drafting CanQuit Addiction: Tobacco Smoking Ce
Slide 9: APIRx Intellectual Property Families
APIRx Intellectual Property Families Extraction 3 Granted 2 Pending Shareholder Presentation 9 API modification 4 Pending Formulation 17 Granted 15 Pending Methods of use 3 Granted 5 Pending 19 granted and 23 pending patents to secure commercial exclusivity and our R&D investment. Some patents meet
Slide 10: APIRx Leadership Team Advisors
APIRx Leadership Team Advisors Professor Dr. John Zajicek MD PhD Univ. of St. Andrews, UK John’s diverse and extensive medical honours and experience includes: MD, Cambridge and St. Mary’s Hospital PhD, Cell Biology at Cambridge and Professor of Medicine at University of St Andrew’s. He is the Chief
Slide 11: Academic research partnerships
Academic research with the Dept. of Neurology on effects of cannabinoids and chewing, in particular pain and spasticity in MS. MedChew TM Rx project. Free University of Amsterdam, The Netherlands University of Plymouth, UK Dept. of Neurology - MS site for MedChew TM Rx projects. University of Nijmeg
Slide 12: Research priorities
Research priorities Combined with Incannex, the APIRx drug portfolio is positioned to yield patent protected products with marketing approval from regulatory agencies across a range of therapeutic areas . The programs outlined on the subsequent slides have been identified as lead assets for developm
Slide 13: APIRx expertise in Drug Delivery Systems
APIRx expertise in Drug Delivery Systems APIRx forms of delivery potentially applicable to Incannex drug combinations. Existing Forms of Delivery РSmoking Рrapid onset and decline, socially unacceptable. РOral spray (Sativex Π) Рsolution contains alcohol and other ingredients to cause dry mouth
Slide 14: Why cannabinoid oral delivery via medicated chewing gum and chewable tablets
Why cannabinoid oral delivery via medicated chewing gum and chewable tablets Medicated chewing gum and chewable tablets (‘MCGT’) is a drug delivery system growing in favour amongst the medical community due to widespread potential applications as an extended - release dosage form that provides a con
Slide 15: Improved bioavailability of CheWell
Improved bioavailability means that even small doses of CBD within MCGTs could be highly effective even without a prescription from a doctor . That is, they would meet the TGA requirements for an OTC product . Increased bioavailability also reduces cost of goods, which increases margins. First marke
Slide 16: Cannabinoid Chewing Gums and chewable tablets for Treatment of Addiction
Opioid use disorder addressable market US$ 64B * Nicotine chewing gum market sales of US$ 5.2B ** in 2020 Cannabinoid Chewing Gums and chewable tablets for Treatment of Addiction APIRx has multiple patents for cannabinoid based drug candidates designed for treatment of addiction to different drug cl
Slide 17: MedChew Rx: Pain and Spasticity in Multiple Sclerosis
Problem Up to 84% of people suffering from MS also experience spasticity, which causes involuntary muscle stiffness and spasms. Pain is also a common symptom in MS, with up to two - thirds of people with MS reporting pain in worldwide studies. Solution MedChew ΠRx is absorbed through the oral mucos
Slide 18: MedChew Dronabinol: Nausea and Vomiting in Chemotherapy
MedChew TM Dronabinol Nausea and Vomiting in Chemotherapy Problem According to the WHO, cancer is one of the leading causes for death. Chemotherapy is utilized by 10 million cancer patients each year. This number will grow by 53% by 2040. Nausea and vomiting are two of the most dreaded cancer treatm
Slide 19: Inflammatory Bowel Disease: CanChew Rx and Suppocan
Problem 68 million people suffer from Inflammatory Bowel Disease globally. Signs and symptoms of both Crohn’s disease and ulcerative colitis include diarrhea, fatigue, and abdominal pain and cramping, reduced appetite, and unintended weight loss . Heretofore, the main medications for IBD are anti -
Slide 20: OraxiMax Periodontal Disease and Gingivitis
OraxiMax TM Periodontal Disease and Gingivitis (Toothpaste and Mouthwash) Problem Up to 50% of adults suffer from moderate to severe periodontitis and/or gingivitis. Heretofore, periodontal disease treatment has been limited to professional dental cleaning and the use of systemic antibiotics. Soluti
Slide 21: Topical cannabinoid development for skin diseases
Problem Hundreds of millions of people suffer with skin diseases that involve inflammation and/or microbial infection. Solution APIRx has developed and patented a combination of CBD and CBG, a minor cannabinoid that also has potent anti - inflammatory activity, in a topical formulation. Combines ant
Slide 22: Ophthalmic conditions
Problem Hundres of millions of people suffer from eye diseases and disorders where inflammation is a contributing factor. Available treatments have inadequate response for many patients and often have unwanted side effects. Solution – APIRx has two granted patents for ophthalmic formulations of cann
Slide 23: APIRx cannabinoid extraction Intellectual Property
APIRx cannabinoid extraction Intellectual Property Proprietary “Ultrapure” extraction methods have the potential to markedly reduce the cost pharmaceutical (cGMP) grade CBD, THC and Cannabigerol (CBG) to reduce the cost of goods for all Incannex products and to ensure that OTC products are price com
Slide 24: APIRx Competitive Advantage
APIRx Competitive Advantage The World’s largest privately held IP portfolio in cannabinoid - based pharmaceuticals. A robust patent filing strategy and diversified drug portfolio including 22 drug development programs . Highly credentialed and experienced specialists in medical, academic and scienti
Slide 25: Short term priorities and value drivers
Short term priorities and value drivers Development of IHL’s six current programs will continue as previously described. Progress will not be disrupted by proposed acquisition. Program Value driver Next steps CheWell for treatment of IBS – OTC product for Australia with potential to extend to global
Slide 26: Opportunity
APIRx has a collection of patents, formulations, clinical trial data and regulatory filings for cannabinoid medicines that provide direct and faster paths to drug product approval. Patients will benefit from earlier access to evidence - based cannabinoid therapies across therapeutic areas that emplo
Slide 27: Media, Investor and Partnership Enquiries
Media Enquiries For media related enquiries please contact: Joel Latham joel@incannex.com.au Investor Enquiries For investor related enquiries please contact: Brad Dilkes investors@incannex.com.au Partnership Enquiries For partnership related enquiries please contact: admin@incannex.com.au incannex.
Incannex Healthcare — Merger or Acquisition (May 2022) on 6ix